[Special Stock] Synergy Inno's History of Supplying Microbial Culture Media ... Also Produces Raw Materials for Samsung Bio's 'mRNA Vaccine'

[Asia Economy Reporter Hyunseok Yoo] Synergy Innovation's stock price is on the rise. The news that Samsung Biologics is adding facilities for the production of mRNA (messenger RNA) vaccine raw materials, enabling the entire production process of mRNA vaccines from raw materials to final product packaging to be carried out domestically, appears to have had an impact. There is speculation that technology transfer negotiations between Samsung Biologics and Moderna may expand to include raw material production. Synergy Innovation, the leading domestic supplier of microbial culture media and a supplier to Samsung Biologics, Celltrion, Seoul Asan Hospital, and Samsung Seoul Hospital, is believed to have attracted attention.

As of 9:40 AM on the 1st, Synergy Innovation was trading at 4,480 won, up 10.21% (415 won) compared to the previous trading day.

Previously, there was a case of a sharp rise when it was reported that a contract for the contract manufacturing of Moderna's messenger ribonucleic acid (mRNA) COVID-19 vaccine was likely. At that time, the news that Synergy Innovation supplied microbial culture media to Samsung Biologics was considered to have influenced the rise.

The day before, Samsung Biologics announced, "We will add mRNA vaccine raw material pharmaceutical production facilities to the existing facilities in Songdo, Incheon, and complete preparations for Good Manufacturing Practice (GMP) by the first half of next year."

This content was produced with the assistance of AI translation services.